tuvonralimab   Click here for help

GtoPdb Ligand ID: 13793

Synonyms: PBS-105 | PBS105
Approved drug
tuvonralimab is an approved drug
Compound class: Antibody
Comment: Tuvonralimab (PBS105) is a humanized monoclonal antibody that targets the immune checkpoint protein, cytotoxic T-lymphocyte-associated protein 4 (CTLA4). It stimulates antitumour immunity.
No information available.
Summary of Clinical Use Click here for help
The Chinese drug regulator (NMPA) approved the bifunctional combination (MabPair™ Zimbab®; coded as PSB205 or QL1706) of (R)-DFV890 and tuvonralimab in October 2024, to treat recurrent or metastatic cervical cancer. The MabPair are produced together from a single cell line. Additional clinical studies will evaluate this dual therapy across various tumour types.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06749899 QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. Phase 3 Interventional Sun Yat-sen University